8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  July 24, 2012

BSD MEDICAL CORPORATION

(Exact name of registrant as specified in its charter)

Delaware	0-10783	75-1590407
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2188 West 2200 South

Salt Lake City, Utah 84119

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code:  (801) 972-5555

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On July 24, 2012, BSD Medical Corporation issued a press release announcing a live investor and analyst webinar update featuring its MicroThermX® Microwave Ablation System scheduled for Tuesday, August 7, 2012 at 2:00 p.m. Eastern time/12:00 p.m. Mountain time.

A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01  Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press release dated July 24, 2012 announcing investor and analyst webinar update

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BSD MEDICAL CORPORATION
Date:  July 26, 2012
	By:  /s/ Dennis P. Gauger
	Name:  Dennis P. Gauger
	Title:    Chief Financial Officer

-2- 

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press release dated July 24, 2012 announcing investor and analyst webinar update

-3-

EX-99.1

BSD Medical Corporation to Host Investor

And Analyst Webinar Update Featuring MicroThermX® on August 7

Live Webinar on the MicroThermX® Microwave Ablation System Scheduled for Tuesday, August 7 at 2:00 p.m. Eastern Time/12:00 p.m. Mountain Time; RSVP Required

Salt Lake City – July 24, 2012 – BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced that it will host an Investor and Analyst Webinar Update featuring its MicroThermX® Microwave Ablation System (MicroThermX®)on Tuesday, August 7, 2012 at 2:00 p.m. Eastern time/12:00 p.m. Mountain time. The event will include presentations from BSD President Harold Wolcott, VP Sales & Marketing Sam Maravich, Jr., and Director of Marketing Sunita Pargass.  The webinar will provide an overview of the addressable market for microwave ablation, technical capabilities of the MicroThermX®, and a progress report on the sales and marketing strategies for the product.

Individuals interested in participating in the webinar may do so by visiting the Investor Relations section of the Company's website at www.BSDMedical.com or by dialing 877-941-6010 from the United States, or 480-629-9643 from outside the United States, and entering conference ID 4554205. We request that you RSVP to the webinar by emailing aomalley@finprofiles.com before 4:00 p.m. Eastern time on Friday, August 3, 2012. An accompanying slide presentation will be available on the Company website.

A telephone replay will be available through August 14, 2012 by dialing 800-406-7325 from the United States, or 303-590-3030 from outside the United States, and entering conference ID 4554205.  A webcast replay will be available for 90 days.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy, which is delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market, and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

Statements contained in this press release that are not historical facts are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date.

Contacts

Dennis Gauger

BSD Medical Corporation

801-972-5555

investor@bsdmc.com

Tricia Ross

Financial Profiles

916-939-7285

tross@finprofiles.com

Amy O’Malley

Financial Profiles

310-278-2700 x10

aomalley@finprofiles.com